Obesity and diabetes are major risk factors for epicardial adipose tissue inflammation by Vyas, V et al.
1
C L I N I C A L  M E D I C I N E
Authorship note: VV, HB, and EGW 
contributed equally to this work. MCF 
and MPL jointly supervised this work.
Conflict of interest: VV and MCF 
received funding from Abbott.
Copyright: © 2021, Vyas et al. This is 
an open access article published under 
the terms of the Creative Commons 
Attribution 4.0 International License.
Submitted: October 28, 2020 
Accepted: July 14, 2021 
Published: August 23, 2021




Obesity and diabetes are major risk factors 
for epicardial adipose tissue inflammation
Vishal Vyas,1,2 Hazel Blythe,1 Elizabeth G. Wood,1 Balraj Sandhar,1 Shah-Jalal Sarker,3  
Damian Balmforth,1,4 Shirish G. Ambekar,4 John Yap,4 Stephen J. Edmondson,4 Carmelo Di Salvo,4 
Kit Wong,4 Neil Roberts,4 Rakesh Uppal,1,4 Ben Adams,4 Alex Shipolini,4 Aung Y. Oo,1,4  
David Lawrence,3,4,5 Shyam Kolvekar,3,4 Kulvinder S. Lall,4 Malcolm C. Finlay,1,2 and M. Paula Longhi1
1William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of 
London, London, United Kingdom. 2Department of Cardiology, Barts Heart Centre, St Bartholomew’s Hospital, London, 
United Kingdom. 3Research Department of Medical Education, UCL Medical School, University College London, London, 
United Kingdom. 4Department of Cardiac Surgery, Barts Heart Centre, St Bartholomew’s Hospital, London, United 
Kingdom. 5University College London Hospitals NHS Foundation Trust, London, United Kingdom.
Introduction
Epicardial adipose tissue (EAT) is the visceral adipose tissue of the heart, covering 80% of its surface and up 
to 20% of its weight (1). EAT is in direct contact with the underlying myocardium without fascial interrup-
tion, allowing direct interactions between the 2 tissues. EAT has been implicated in a host of cardiovascular 
diseases (2) and has been proposed as a transducer (3) of the effects of systemic conditions such as obesity on 
the heart. Significant associations between EAT thickness and cardiovascular risk factors have been report-
ed, including diabetes (4) and hypertension (5). Although variable (4, 6, 7), a relationship has been described 
between EAT size and the severity of coronary artery disease (CAD) (8) as well as cardiovascular events (9, 10). 
BACKGROUND. Epicardial adipose tissue (EAT) directly overlies the myocardium, with changes in its 
morphology and volume associated with myriad cardiovascular and metabolic diseases. However, 
EAT’s immune structure and cellular characterization remain incompletely described. We aimed to 
define the immune phenotype of EAT in humans and compare such profiles across lean, obese, and 
diabetic patients.
METHODS. We recruited 152 patients undergoing open-chest coronary artery bypass grafting 
(CABG), valve repair/replacement (VR) surgery, or combined CABG/VR. Patients’ clinical and 
biochemical data and EAT, subcutaneous adipose tissue (SAT), and preoperative blood samples 
were collected. Immune cell profiling was evaluated by flow cytometry and complemented by gene 
expression studies of immune mediators. Bulk RNA-Seq was performed in EAT across metabolic 
profiles to assess whole-transcriptome changes observed in lean, obese, and diabetic groups.
RESULTS. Flow cytometry analysis demonstrated EAT was highly enriched in adaptive immune 
(T and B) cells. Although overweight/obese and diabetic patients had similar EAT cellular profiles 
to lean control patients, the EAT exhibited significantly (P ≤ 0.01) raised expression of immune 
mediators, including IL-1, IL-6, TNF-α, and IFN-γ. These changes were not observed in SAT or blood. 
Neither underlying coronary artery disease nor the presence of hypertension significantly altered 
the immune profiles observed. Bulk RNA-Seq demonstrated significant alterations in metabolic 
and inflammatory pathways in the EAT of overweight/obese patients compared with lean controls.
CONCLUSION. Adaptive immune cells are the predominant immune cell constituent in human EAT 
and SAT. The presence of underlying cardiometabolic conditions, specifically obesity and diabetes, 
rather than cardiac disease phenotype appears to alter the inflammatory profile of EAT. Obese 
states markedly alter EAT metabolic and inflammatory signaling genes, underlining the impact of 
obesity on the EAT transcriptome profile.
FUNDING. Barts Charity MGU0413, Abbott, Medical Research Council MR/T008059/1, and British 
Heart Foundation FS/13/49/30421 and PG/16/79/32419.
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However, EAT size does not necessarily correlate with the degree of inflammation observed (3), and how EAT 
inflammation correlates with the severity of CAD remains controversial (11).
The pivotal role of  inflammation in the pathogenesis of  many cardiovascular disorders is increasingly 
recognized (12, 13). The EAT has been identified as a rich local source of  vasoactive molecules, pro- and 
antiinflammatory adipokines, growth factors, and other agents that can exert paracrine and vasocrine 
effects on the myocardium (1, 8). Inflammatory mediators released by EAT may directly contribute to 
the inflammation of  the myocardium and coronary arteries. Indeed, higher levels of  the proinflammatory 
mediators IL-1β, IL-6, monocyte chemoattractant protein 1 (MCP1), and TNF-α and reduced levels of  
adiponectin were observed in the EAT of  CAD and diabetic patients (14–17). Additionally, increased infil-
tration of  “proinflammatory” CD11c+ versus “antiinflammatory” CD206+ macrophages was observed in 
the EAT of  CAD patients (18). Aside from these reports, much of  our current understanding of  adipose 
tissue–mediated inflammation is derived from studies of  noncardiac depots, such as abdominal visceral 
adipose tissue, where proinflammatory macrophages predominate (19). The description of  the inflamma-
tory cell population and pathways in EAT in humans remains incomplete, and an understanding of  how 
these may vary between conditions such as severe CAD and valvulopathy is absent.
Here, we aimed to describe the human EAT immune infiltrate and provide comparisons with subcu-
taneous adipose tissue (SAT) and blood inflammatory profiles (adipose tissue and systemic comparators 
accessible during cardiac surgery). Significant challenges in accessing human EAT were overcome by lim-
iting this investigation to patients undergoing cardiac surgery for 2 commonly encountered cardiovascular 
diseases: severe CAD and valvular heart disease without severe CAD. Further, we hypothesized that the 
underlying risk factors associated with the EAT, specifically obesity, diabetes, and hypertension rather than 
CAD per se, alter the inflammatory profile of  EAT. Here, we first outline the immune profile of  EAT and 
how it differs from SAT and blood, demonstrating that T cells and not macrophages were the predominant 
immune cell population in both EAT and SAT. We then show that CAD and valvular heart disease patients 
exhibited a similar pattern of  inflammation. We go on to illustrate that obesity and diabetes drove changes 
in immune infiltrates and that these changes were uniquely observed in the EAT, underlining its critical 
significance in cardiovascular disease pathophysiology.
Results
T cells are the primary immune cell type present in EAT. To gain a more complete understanding of  the immune 
profile of  EAT, we investigated the presence of  key immune populations by flow cytometry. The gating strate-
gy is outlined in Supplemental Figure 1; supplemental material available online with this article; https://doi.
org/10.1172/jci.insight.145495DS1. The most striking differences in the immune profile were noted between 
blood and adipose tissue. In the blood, 60% of immune cells were neutrophils and 3% adaptive immune cells 
(B and T cells) while in the EAT and SAT, adaptive immune cells made up approximately 60% of immune 
cells and neutrophils less than 7% cells (Figure 1A). In addition, the immune infiltrate was significantly low-
er (P ≤ 0.001) in SAT than EAT. We focused particularly on T cell subsets given adipose tissue is now a 
well established reservoir of  memory T cells (20, 21). We used unsupervised t-distributed stochastic neighbor 
embedding (t-SNE) plots to investigate the presence of  naive T, central memory T (TCM), effector memory T 
(TEM), and tissue-resident memory T (TRM) cells in SAT, EAT, and blood (Figure 1B). As expected, CD4+ 
and CD8+ TRM cells made up a sizeable proportion of  the T cell repertoire in adipose tissues but were absent 
in blood. TRM cells in the adipose tissue were CD103–, CD69+, and programmed cell death protein 1–posi-
tive (PD-1+) (Supplemental Figure 1), which was consistent with those observed in murine models (20).
Next we evaluated the phenotype of  those T cells by intracellular cytokine staining in a small cohort of  
patients undergoing coronary artery bypass grafting (CABG) (n = 17) and valve repair/replacement (VR) 
(n = 8) where sufficient adipose tissue was available for additional analyses. We found that IFN-γ was the 
most highly expressed cytokine in both CD4+ and CD8+ T cells, with negligible levels of  IL-17– and IL-22–
producing T cells (Supplemental Figure 1C). However, there were marked differences in IFN-γ production 
in each individual patient’s EAT compared with each patient’s blood and SAT, highlighting that blood is 
not necessarily a good gauge of  tissue-level inflammation (Figure 1C).
EAT inflammation is independent of  CAD severity. We set out to investigate whether the immune pro-
file of  EAT from patients with severe CAD (CABG patients) differed from those with nonsevere CAD 
(VR patients). There were marked differences in the groups. As expected, patients were typically in their 
seventh decade of  life; CABG and combined CABG/valve surgery patients had a high proportion of  
3
C L I N I C A L  M E D I C I N E
JCI Insight 2021;6(16):e145495  https://doi.org/10.1172/jci.insight.145495
cardiovascular risk factors, including diabetes, hypertension, hyperlipidemia, and a history of  smoking. 
Medications reflected their underlying cardiac comorbidities. Notably, baseline inflammatory markers 
(C-reactive protein and neutrophil/lymphocyte ratio) were similar between the groups (Table 1). In order 
to first comprehensively characterize the key immune populations present in the blood and adipose tissue 
of  patients with severe versus nonsevere CAD, we used the CABG and VR surgery cohorts. Given only 
16 patients had combined CABG/valve surgery, the group was too small for inferential statistical analysis 
following the propensity matching and hence was not included in this analysis. Patients with a history of  
myocardial infarction were excluded. A total of  48 patients in the CABG and VR surgery groups were 
thus included (Table 2) following propensity matching.
The numbers of  macrophages remained similar between groups as did the proportion of  M2-polarized 
“antiinflammatory” CD206+ macrophages. Similarly, no significant differences (P ≤ 0.9) were noted in 
numbers of  key immune cells in both adipose tissue and blood across both groups (Figure 2 and Supple-
mental Figure 2). Similarly, no differences in expression levels of  immune mediators were observed across 
the 2 groups (Figure 2C). Reviewing cell numbers in blood and adipose tissue, again no significant changes 
in T cell subsets were noted, nor were there any differences in IFN-γ production across the EAT, SAT, or 
blood (Figure 2, D–F). Thus, our data demonstrate that CAD is not associated with alterations in immune 
cell numbers or inflammatory mediator levels in EAT.
Obesity promotes EAT inflammation. Hypercholesterolemia, overweight/obesity, hypertension, and dia-
betes are known to be key risk factors for the development of  CAD. Thus, the next step was to identify 
whether these conditions are associated with an altered inflammatory picture observed in different patients.
First, we considered the effect of  obesity as this is most likely to affect adipose tissue biology direct-
ly, inducing an inflammatory response. Given that patients with type 2 diabetes (T2D) were in general 
prescribed antihyperglycemic medications, they were analyzed as a separate group despite having similar 
BMIs to the overweight/obese cohort. Table 3 details the demographic and clinical characteristics of  the 
patients utilized for the overweight/obesity and T2D group analysis.
Absolute numbers of  key adaptive immune cells were similar across groups (Figure 3, A, B, D, and 
E; and Supplemental Figure 3). However, the immune mediator profile was dramatically altered unique-
ly in the EAT compared with blood and SAT (Figure 3C and Supplemental Figure 4). Overweight/
obese and T2D patients were observed to have greatly elevated expression levels of  the same proinflam-
matory immune mediators, specifically a 5- to 10-fold increase in IL-1, IL-6, TNF-α, and IFN-γ. IL-6 
and TNF-α can be produced by myeloid cells and adipocytes, while IL-1 and IFN-γ are mainly released 
Figure 1. CD4+ T cells are the dominant immune population in EAT and SAT. (A) Pie chart illustrating relative proportions of CD45+ cells from the 
stromal-vascular fraction across tissues (n = 152). (B) Representative t-SNE plot to cluster different T cell subsets into a 2-dimensional plot across 
blood, EAT, and SAT. (C) IFN-γ levels produced by T cells in blood, EAT, and SAT (n = 25). Each color line represents the same patient.
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by immune cells, e.g., myeloid cells and T cells, respectively. All these cytokines are known to contribute 
to adipose tissue inflammation and insulin resistance. As expected, overweight/obese and T2D patients 
exhibited increased expression levels of  the adipokine leptin. Notably, levels of  adiponectin were ele-
vated in obese patients. The proportion of  TEM and TRM cells was similar between groups. Yet a clear 
increase in CD4+IFN-γ+ and CD8+IFN-γ+ T cells could be observed in both overweight/obese and T2D 
groups, seeing as T cells are the main producer of  IFN-γ. The level of  immune mediators in blood was 
similar, with the exception of  TNF-α that was elevated in the overweight/obese cohort. These data indi-
cate that although the cellular immune infiltrate in EAT remains the same, obesity and diabetes induce 
a change in phenotype toward a proinflammatory state.
Obesity induces extensive EAT remodeling. In order to further investigate the differences in gene expres-
sion in EAT between lean and overweight/obese and T2D patients, we performed bulk RNA-Seq. The 
thresholds of  differentially expressed genes were fold change more than 2 and adjusted P value less 
than 0.05. There were 133 differentially expressed genes in overweight/obese compared with lean EAT 
patients, while 94 were found to be significantly upregulated in T2D patients (Figure 4A and Supple-
mental Figure 5A). Inflammatory and metabolic genes were differentially regulated in both overweight/
obese and T2D samples compared with lean (Figure 4B and Supplemental Tables 1 and 2). Upregulation 
of  inflammatory genes indicating activation of  myeloid and lymphoid cells included IL6, IL1b, CXCL8, 
CCL3, NLRP3, ATF3, OSM, CD83, GPR183, VCAN, CCR3, CXCL12, and CCL2. T2D patients showed a 
lower expression of  inflammatory genes in EAT compared with overweight/obese (Figure 4, A and B, 
and Supplemental Figure 5B). A similar trend was observed in the real-time PCR (RT-PCR) and intracel-
lular cytokine production by T cells (Figure 3, C and F). Obesity induces a profound metabolic rewiring 
in EAT, with downregulation of  genes associated with glucose metabolism (e.g., SLC24A, CS, GPT, 
OGDH, ACO2, GPI, LDHD) and lipid metabolism (e.g., GYS2, GPAT3, CRAT, FASN, ACADVL, DGAT1, 
DGAT2, NAT8L, SCD) as well as changes in genes related to adipogenesis (HES1, MXD3, NR4A2, RGS2, 
PPP1R15B, ADAMTS1, CEBPD, KDM7A). The metabolic phenotype was more evident in EAT from 
diabetic patients (Figure 4B and Supplemental Figure 5, C and D). Interestingly, certain genes associated 
Table 1. Clinical characteristics of all study participants
Variable VR (n = 54) CABG (n = 82) Combined CABG/valve 
surgery (n = 16)
P value
Age (years) 67.4 ± 11 64.9 ± 9.9 70.4 ± 6.8 0.08
BMI (kg/m2) 26.6 (22.9–29.9) 29.2 (25.4–31.6) 28.9 (26.5–31.1) 0.008A
Male sex (%) 34 (63.0) 67 (81.7) 14 (87.5) 0.02A
Female sex (%) 20 (37.0) 15 (18.3) 2 (12.5)
Hypertension (%) 28 (51.8)  61 (74.4) 12 (75) 0.02A
Type 2 diabetes 8 (14.8) 24 (29.3) 8 (50) 0.004B
Hyperlipidemia (%) 26 (48.1) 58 (70.3) 8 (50) 0.02A
Smoking history (%) 20 (37.0) 54 (65.8) 9 (56.2) 0.004B
Prior myocardial infarction (%) 10 (18.5) 36 (43.9) 0 (0) 0.0003C
Prior atrial fibrillation (%) 20 (37.0) 7 (8.5) 3 (18.8) 0.0002C
Postoperative atrial fibrillation (%) 7 (13.0) 18 (21.9) 8 (50) 0.04A
Left ventricular ejection fraction (%) 59 (55–63) 53 (46–60) 51 (40–60) 0.001B
Preoperative use of beta blockers (%) 22 (40.7) 64 (78.0) 9 (56.3) 0.001B
Preoperative use of ACE inhibitors/ARBs (%) 24 (44.4) 59 (71.9) 8 (50) 0.004B
Preoperative use of aspirin (%) 12 (22.2) 63 (76.8) 12 (75) 0.0001C
Preoperative use of statins (%) 30 (55.5) 68 (82.9) 13 (81.2) 0.001B
Preoperative use of metformin (%) 4 (7.4) 17 (20.7) 3 (18.7) 0.04A
C-reactive protein (mg/L) 3 (1–5.5) 2 (1–5) 1 (1–8.2) 0.36
Neutrophil/lymphocyte ratio 2.1 (1.7–3.1) 1.9 (1.4–3.2) 2.6 (1.7–3.4) 0.2
BMI, left ventricular ejection fraction, C-reactive protein, and neutrophil/lymphocyte ratio are shown as median and interquartile range; remaining rows are shown 
as mean ± SD. Two-way ANOVA/Kruskal-Wallis for continuous data with Dunnett’s T3 (or Dunn’s for nonparametric data) multiple comparisons posttest applied. 
χ2/Fisher’s exact test for categorical data was used where appropriate. AP < 0.05. BP < 0.005.  CP < 0005. ACE, angiotensin-converting enzyme; ARBs, angiotensin II 
receptor blockers.
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with CAD were dysregulated in obese EAT, such as HBEGF, ADAMTS1, and ADAMTS4 while the novel 
adipokine spexin (SPX), which regulates adipose tissue inflammation and was shown to protect cardio-
myocytes from hypoxia-induced metabolic distress (22), was downregulated in EAT from both obese and 
diabetic patients. Overall, these data highlight significant metabolic and inflammatory changes in EAT 
that obesity induced.
EAT inflammation is not associated with hypertension. EAT volume was found to be increased in hyper-
tensive compared with normotensive patients (5). Thus, we investigated if  the presence of  hypertension 
alters the EAT inflammatory state (Table 4) and found that it did not (P ≥ 0.14). Both hypertensive and 
nonhypertensive (control) patients demonstrated similar immune cell profiles in the blood, EAT, and SAT 
(Figure 5, A and B, and Supplemental Figure 6) alongside similar relative expression levels of  key immune 
mediators (Figure 5C). Looking at specific T cell subsets and their phenotype, again similar absolute num-
bers of  T cell subsets and IFN-γ production were seen across both groups and across tissues (Figure 5, D–F, 
and Supplemental Figure 6). Hence, we show that hypertension as a cardiovascular risk factor in isolation 
is not a driver of  EAT inflammation.
Discussion
A number of  previous analyses (11, 15) studying patients undergoing cardiac surgery with and without 
significant CAD (CABG vs. VR surgery patients) suggest that it is the specific adipose tissue depot, name-
ly EAT, that drives the unique inflammatory changes observed. With EAT’s anatomical intimacy with 
the myocardium and lack of  fascial boundaries between them, immune mediators can have a direct and 
potentially deleterious impact on the heart. This highlights the unique significance of  EAT in giving an 
indication of  the local tissue environment.
To date and despite a wealth of  data indicating a link between EAT volume and cardiovascular disease, 
in-depth investigations of  EAT inflammation remain sparse. Indeed, we still lack a detailed overview of  the 
immune profile of  EAT and how it differs between SAT and blood samples and in different cardiovascular 
conditions. Here we show a clear enrichment of  adaptive immune cells, in particular CD4+ T cells, in the 
adipose tissue (EAT and SAT) compared with blood, where neutrophils are the dominant cell type. Of  
note, much of  the earlier literature has focused on innate immune cells, such as macrophages within EAT 
(16, 18), yet the immune profiling illustrates these represent a lower proportion of  the immune (CD45+ ) 
cell population compared with adaptive immune cells. Both EAT and abdominal adipose tissue are derived 
Table 2. Propensity-matched patients for VR versus CABG surgery comparison
Variable VR surgery (n = 24) CABG surgery (n = 24) P value
Age (years) 66.8± 12.4 65 ± 7.9 0.54
BMI (kg/m2) 26.4 (22.1–29.9) 27.8 (25.2–30.1) 0.23
Male sex (%) 14 (58.3) 19(79.2) 0.22
Female sex (%) 10 (41.7) 5 (20.8)
Hypertension (%) 13 (54.2) 15 (62.5) 0.77
Type 2 diabetes 3 (12.5) 6 (25) 0.46
Hyperlipidemia (%) 15 (62.5) 19 (79.1) 0.34
Smoking history (%) 10 (41.7) 16 (66.7) 0.15
Prior myocardial infarction (%) 0 (0) 0 (0) 0.99
Prior atrial fibrillation (%) 6 (25) 5 (20.8) 0.73
Postoperative atrial fibrillation (%) 7 (29.2) 4 (16.7) 0.30
Left ventricular ejection fraction (%) 60 (60–63) 58 (55–60) 0.07
Preoperative use of beta blockers (%) 12 (50) 18 (75) 0.13
Preoperative use of ACE inhibitors/ARBs (%) 10 (41.7) 11 (45.8) 0.99
Preoperative use of aspirin (%) 5 (20.8) 12 (50) 0.07
Preoperative use of statins (%) 13 (54.2) 17(70.8) 0.37
Preoperative use of metformin (%) 2 (14.3) 5 (20.8) 0.99
C-reactive protein (mg/L) 3.8 (1.7–5.2) 2.7 (1.3–3.8) 0.13
Neutrophil/lymphocyte ratio 2.5 (1.6–2.9) 2.2 (1.5–2.4) 0.27
Two-tailed Student’s t test/Mann-Whitney U test for continuous data or χ2/Fisher’s exact test for categorical data was used where appropriate.
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Figure 2. Comparison of EAT immune profiling between CAD patients and controls. (A and B) Absolute number of immune cells in CABG and VR 
patients across blood (A) and EAT (B) (n = 24 patients/group). (C) Relative expression levels of immune mediators in blood and EAT, respectively (n = 
24 patients/group). Expression levels were normalized to GAPDH expression. Bars represent expression in CABG patients compared with VR surgery, 
which was set at 1 and indicated with dotted lines. Error bars show the geometric mean. (D and E) Graphs showing T cell subsets in blood (D) and EAT 
(E). (F) IFN-γ production among live CD4+ and CD8+ T cells in blood, EAT, and SAT, respectively (n = 7–8 patients/group). Statistical significance was 
determined by the Mann-Whitney U test, and data are represented as median and interquartile range.
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from the splanchnopleuric mesoderm (1), and both tissues utilize the same vasculature and lymph drainage 
as their underlying organs, the intestine and myocardium, respectively. However, we have demonstrated 
EAT is dominated by adaptive immune cells but abdominal adipose tissue by macrophages (23). This 
would suggest that it is the anatomical location of  the adipose tissue that determines its immune profile.
The notable finding of  TRM cells within the EAT is deserving of  comment. These have not previously 
been characterized in EAT to our knowledge. As the name indicates, TRM cells remain local to the tissue, 
affording long-lasting immune surveillance, and can rapidly reactivate and recruit circulating T cells when 
required (24). Their presence enables adipose tissue to act as a local source of  adaptive immune cells; such 
organ-specific immunity has been previously described in other organs (25). Notably, TRM cells are high 
in PD-1 expression; TRM cell reactivation has been implicated in numerous cancers, but the subset’s exact 
role in the heart remains enigmatic (26).
We have highlighted that blood and SAT may offer a comparative lack of  insight into the local tissue 
environment, given the dominant immune mediator produced from T cells (IFN-γ) can vary considerably 
among tissues in a single individual. This is a critical point as blood is typically assayed for its accessibil-
ity in giving an indication of  the patient’s condition and inflammatory status, yet blood may bear little 
correlation with the local tissue inflammation. Indeed, this point was highlighted in one of  the earliest 
descriptions of  EAT inflammatory mediators (14). Clinicians should be mindful of  the limitations in 
insights available from blood analysis alone.
A key finding is that once underlying cardiovascular risk factors are balanced, we have demonstrated no 
differences in the inflammatory profile between severe versus nonsevere CAD. Some previous publications 
(15, 27, 28) have reported the EAT of  patients with significant CAD to have a unique inflammatory profile. 
However, it is noteworthy that many of  these reports failed to control for other important cardiometabolic 
conditions, such as diabetes and overweight/obesity (16–18), or those predominantly affecting lean individ-
uals (28), which are not typical of  patients undergoing cardiac surgery. A significant strength of  our work is 
that the large patient cohort allowed propensity matching to be performed, reducing bias between our patient 
groups. Our extensive comparison of  a range of  immune cells and immune mediators shows the immune 
Table 3. Propensity-matched patients for overweight/obese, diabetic, and control patients
Variable Lean nondiabetic  
(BMI < 25) (n = 30)
Overweight/obese 
nondiabetic (BMI ≥ 25)  
(n = 30)
Overweight/obese (BMI ≥ 
25) type 2 diabetic  
(n = 30)
P value
Age (years) 66.1 ± 12.2 65.7 ± 8.8 66.1 ± 8.4 0.98
BMI (kg/m2) 22.8 ± 1.5 30.3 ± 2.5 30.5 ± 3.6 N/A
Male sex (%) 20 (66.6) 23 (76.7) 22 (73.3) 0.51
Female sex (%) 10 (33.3) 7 (23.3) 8 (26.7)
Hypertension (%) 17 (56.7) 17 (56.7) 21 (70) 0.47
Hyperlipidemia (%) 17 (56.7) 15 (50) 20 (66.7) 0.42
Smoking history (%) 14 (46.7) 20 (66.7) 15 (50) 0.24
Prior myocardial infarction (%) 7 (23.3) 6 (20) 11 (36.7) 0.27
Prior atrial fibrillation (%) 7 (23.3) 3 (10) 6 (20) 0.37
Postoperative atrial fibrillation (%) 8 (26.7) 4 (13.3) 6 (20) 0.43
Left ventricular ejection fraction (%) 54.7 (49–60) 55.8 (52–60) 53.7 (50–57) 0.35
Preoperative use of beta blockers (%) 15 (50) 14 (46.7) 21 (70) 0.08
Preoperative use of ACE inhibitors/ARBs (%) 12 (40) 19 (63.3) 20 (66.7) 0.25
Preoperative use of aspirin (%) 14 (46.7) 16 (53.3) 21 (70) 0.06
Preoperative use of statins (%) 17 (56.7) 21 (70) 28 (93.3) 0.005A
C-reactive protein (mg/L) 2.1 (1.4–3.3) 3.6 (2.5–5.1) 2.5 (1.7–3.8) 0.1
Neutrophil/lymphocyte ratio 2 (1.6–3.2) 2.4 (1.9–3.1) 1.8 (1.4–4.1) 0.7
VR surgery (%) 15 (50) 13 (43.3) 9 (30) 0.27
CABG surgery (%) 13 (43.3) 15 (50) 18 (60) 0.43
Combined CABG/valve surgery (%) 2 (6.7) 2 (6.7) 3 (10) 0.85
Two-way ANOVA/Kruskal-Wallis for continuous data with Dunnett’s T3 (or Dunn’s for nonparametric data) multiple comparisons posttest applied. χ2/
Fisher’s exact test for categorical data was used where appropriate. AP < 0.005.
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Figure 3. Comparison of EAT immune profiling between obese/overweight and T2D patients and controls. (A and B) Absolute number of immune cells 
in overweight/obesity (O/O) and T2D patients across blood (A) and EAT (B) (n = 30 patients/group). (C) Relative expression of immune mediators in over-
weight/obesity and T2D patients compared with lean nondiabetic patients across blood and EAT (n = 30 patients/group). Gene expression was normalized 
to GAPDH and control set as 1, indicated with dotted lines. Error bars show the geometric mean. (D and E) Graphs showing T cell subsets in blood (D) and 
(E) EAT. (F) IFN-γ production among live CD4+ and CD8+ T cells in blood, EAT, and SAT, respectively (n = 6 patients/group). Statistical significance was 
determined by the Kruskal-Wallis test with Dunn’s multiple comparisons posttest correction applied. Significance denoted as *P < 0.05, **P < 0.005, ***P 
< 0.0005, and data are represented as median and interquartile range.
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profile to be similar in patients with severe (CABG) and nonsevere (VR) CAD across blood, EAT, and SAT. 
Indeed, no differences in absolute numbers of  immune cells were observed in overweight/obese patients or 
those with diabetes. However, the immune mediators are greatly elevated in both overweight/obesity and 
diabetes compared with lean patients. In EAT, TNF-α, IFN-γ, IL-1, IL-6, and leptin levels were all elevated 
several-fold in both of  these groups. Inflammation is a key mechanism of  cardiovascular disease. Proin-
flammatory cytokines, such as IL-1 and TNF-α, can amplify local inflammation, regulate endothelial cell 
Figure 4. Differentially expressed genes in EAT from obese/overweight and T2D patients compared with lean. (A) Heatmap of differentially expressed genes 
in EAT, cutoff: adjusted P < 0.05; log2 fold change > 1. (B) Bars represent gene expression value for the top 40 differentially expressed genes in all 3 groups.
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activation, and induce ROS production and cardiomyocyte apoptosis. Bulk RNA-Seq transcriptomic analy-
sis further confirmed this finding. Proinflammatory cytokines were elevated in overweight/obese EAT and 
to a lesser extent in EAT from T2D patients. Pathway enrichment analysis further indicated upregulation 
of  pathways associated with adaptive immune responses in addition to monocyte/macrophage activation. 
A reduced inflammatory response in T2D patients could be attributed to the antidiabetic drug metformin, 
which is considered to have an antiinflammatory effect (29). The overwhelming majority of  T2D patients 
in our cohort were on metformin, given it is a first-line indicated drug for T2D patients. The study lacked 
statistical power to evaluate the effect of  metformin in EAT inflammation. Cytokine-targeting therapies have 
emerged as possible noninvasive treatments for heart disease. Considering that adipose tissue is the primary 
organ affected by overnutrition and given the anatomical proximity among EAT, coronary arteries, and 
myocardium, it is possible to envisage EAT as the primary source of  heart inflammation in obesity.
T cells were found to be the main producers of  IFN-γ. Certain mediators have previously been 
described to be elevated in the EAT (15, 27) but not attributed to specific comorbidities through a 
robust propensity-matched analysis. Similarly, a host of  studies have illustrated increased EAT size in 
patients with increased BMI (4, 6) and diabetes (15, 27), but a detailed understanding of  changes in 
immune cell types and inflammatory mediators has been lacking. Importantly, we have demonstrated 
that adiponectin was uniquely elevated in the overweight/obese group. Reduced adiponectin in EAT 
was found to be associated with atherosclerotic plaque development, but this association is not con-
sistent between studies (16, 18, 30), with reports not accounting for potential confounding variables, 
such as BMI (16), and with patients being entirely or almost exclusively men (16, 31). Adiposity and 
diabetes appear to alter specific inflammatory mediators rather than having a more holistic impact 
on the immune phenotype. This is crucial for future studies analyzing immune differences of  adipose 
tissue between patients with varying metabolic risk profiles.
Infiltration of  inflammatory cells in expanding adipose tissue can result in adipocyte dysfunction and 
metabolic dysregulation. Several human studies, mainly in subcutaneous fat, have linked obesity to reduced 
mitochondrial oxidative metabolism and biogenesis as well as to impaired glucose and lipid metabolism in 
adipose tissue (32, 33). The insulin-regulated glucose receptor GLUT4 is downregulated in obese adipose 
tissue but not skeletal muscle; however, deletion of  GLUT4 selectively in adipose tissue is sufficient to 
Table 4. Propensity-matched patients for hypertensive and control patients
Variable Hypertensive group  
(n = 32)
Control nonhypertensive 
group (n = 32)
P value
Age (years) 67.4 ± 7.9 65.8± 13 0.56
BMI (kg/m2) 28.1 (23.2–29.9) 27.5 (21.1–29.8) 0.87
Male sex (%) 25 (78.1) 24 (75) 0.99
Female sex (%) 7 (21.9) 8 (25)
Hyperlipidemia (%) 17 (53.1) 17 (53.1) 0.99
Smoking history (%) 15 (46.9) 20 (62.5) 0.31
Prior myocardial infarction (%) 8 (25) 8 (25) 0.99
Prior atrial fibrillation (%) 6 (18.7) 5 (15.6) 0.74
Postoperative atrial fibrillation (%) 8 (25) 6 (18.7) 0.54
Left ventricular ejection fraction (%) 55 (48–60) 60 (55–60) 0.53
Preoperative use of beta blockers (%) 16 (50) 21 (65.6) 0.31
Preoperative use of ACE inhibitors/ARBs (%) 22 (68.7) 16 (50) 0.2
Preoperative use of aspirin (%) 24 (75) 21 (65.6) 0.58
Preoperative use of statins (%) 3 (9.4) 4 (12.5) 0.99
Preoperative use of metformin (%) 2 (1–6) 3 (2–9) 0.14
C-reactive protein (mg/L) 1.9 (1.4–3.9) 2.3 (1.8–2.8) 0.7
Neutrophil/lymphocyte ratio 7 (21.9) 6 (18.7) 0.99
CABG surgery (%) 14 (43.8) 15 (46.9) 0.99
VR surgery (%) 15 (46.9) 15 (46.9) 0.99
Combined CABG/valve surgery (%) 3 (9.4) 2 (6.3) 0.99
Two-tailed Student’s t test/Mann-Whitney U test for continuous data or χ2/Fisher’s exact test for categorical data was used where appropriate.
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Figure 5. Comparison of EAT immune profiling between hypertensive patients and controls. (A and B) Absolute number of immune cells in hyperten-
sive and control patients across blood (A) and EAT (B) (n = 32 patients/group). (C) Relative expression of immune mediators in hypertensive versus con-
trol patients across blood and EAT (n = 32 patients/group). Gene expression was normalized to GAPDH and control set as 1, indicated with dotted lines. 
Error bars show the geometric mean. (D and E) Graphs showing T cell subsets in blood (D) and EAT (E). (F) Graphs represent IFN-γ production among live 
CD4+ and CD8+ T cells in blood, EAT, and SAT, respectively (n = 6 patients/group). Statistical significance was determined by Mann-Whitney U test, and 
data are represented as median and interquartile range.
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induce insulin resistance (34). Downregulation of  GLUT4 results in reduced adipocyte glucose uptake and 
de novo fatty acid synthesis (35), contributing to systemic metabolic perturbations in obesity. Our findings 
in EAT are in agreement with previous studies showing decreased glucose metabolism and lipid synthesis 
in obese adipose tissue from other sites (abdominal and subcutaneous).
Adipose tissue is one of the main sites of mitochondrial branched-chain amino acid (BCAA; leucine, valine, 
and isoleucine) catabolism (36). Impaired BCAA metabolism correlates with insulin resistance, altered cardiac 
metabolism, and greater risk of cardiovascular disease (33, 37, 38). Genes associated with BCAA catabolism, 
including ACAD8, ALDH6A1, LDH9A1, BCKDHA, BCKDHB, and HADH, were downregulated in EAT from 
overweight/obese and T2D patients, which may contribute to cardiac dysfunction. Overall, our data suggest 
that the metabolic perturbation observed in obese adipose tissue from other sites is similarly observed in EAT.
Finally, EAT size has been associated with the presence of  hypertension (5, 39). However, hypertension 
does not appear to specifically affect the EAT immune phenotype. First, this highlights a point alluded to 
earlier that EAT size does not necessarily correlate with the degree of  inflammation. Second, when consid-
ering the studies assessing hypertension and EAT, it is noteworthy that hypertensive patients often tend to 
be comorbid with overweight/obesity and T2D, which when adjusted for, reduces the significance of  the 
association with EAT size and hypertension (7, 39). This is consistent with the changes observed uniquely 
in the overweight/obese and T2D groups in our study, when comorbidities have been adjusted for.
A number of  limitations to our study are important to recognize. The number of  patients per 
group was relatively small compared with other observational studies, but this was the largest detailed 
immunophenotype analysis in EAT. In addition, the immune mediator alterations observed in the EAT 
of  overweight/obese and diabetic patients are independent associations. A causal relationship between 
these conditions and EAT inflammation cannot be established given the inability to perform a random-
ized controlled trial with the prolonged period required for conditions such as obesity and diabetes to 
exert an impact on EAT. Moreover, EAT can only be ethically sampled during cardiac surgery (and not 
in healthy volunteers, for instance). Due to the challenges in safely harvesting EAT, we were not able to 
perform multisite EAT sampling to assess whether regional differences in the EAT inflammatory profile 
could be observed from the same patient. We utilized the CABG versus VR surgery groups to compare 
severe versus nonsevere CAD. While we recognize these are not ideal comparison groups, as alluded 
to above, healthy controls could of  course not be recruited. The decision for CABG was based on a 
joint cardiology/cardiac surgery multidisciplinary team discussion concluding severe CAD was pres-
ent, warranting CABG. VR alone was performed with a similar multidisciplinary team discussion con-
cluding there was not severe enough CAD to require concomitant CABG and VR. Thus, VR was used 
as a control group accepting the limitations as outlined above. In the context of  these limitations, we 
surmised that a propensity-matched analysis using fresh human tissue samples was the best approach to 
study the risk factor/EAT inflammation relationship.
In summary, we have performed a detailed immune analysis of  EAT, SAT, and blood in a substan-
tial cohort of  clinically well phenotyped patients undergoing cardiac surgery. We have demonstrated 
the overall immune profile was dominated by adaptive immune cells in EAT and SAT compared with 
neutrophils in blood, and the blood was not necessarily an accurate gauge of  tissue-level inflammation. 
Finally, we have shown that key cardiometabolic conditions, namely overweight/obesity and T2D, were 
independently associated with significant changes in the EAT inflammatory picture rather than just the 
presence or absence of  severe CAD.
Methods
Study population and sample collection. Adult patients (≥18 years) undergoing open-chest CABG, VR, or com-
bined CABG/valve surgery were recruited from Barts Heart Centre, St Bartholomew’s Hospital, from 2017 
to 2020 (n = 152). Exclusion criteria included patients with underlying congenital heart disease, those with 
coexisting systemic inflammatory/neoplastic disorders, and those on immunomodulatory agents. Fasting 
blood samples were collected preoperatively in the anesthetic room. Approximately 0.8–1 g of  adipose 
tissue samples were collected in ice-cold phosphate-buffered saline with 2% fetal bovine serum. SAT was 
collected immediately following the median sternotomy incision, and EAT was obtained following opening 
up of  the pericardial sac with tissue typically collected over the body of  the right ventricle. Following tissue 
collection, samples were transferred to the William Harvey Research Institute, Queen Mary University of  
London, for further processing (Supplemental Figure 7).
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The protocols of  the studies complied with the Declaration of  Helsinki, and all patients provided 
informed written consent. The demographic characteristics are presented in Tables 1–4.
Sample processing. Fasting blood samples were collected preoperatively to include 6.5 mL of  peripheral 
blood divided into 2.5 mL collected in a PAXgene (PreAnalytiX) tube for RNA isolation and the remain-
ing 4 mL in an EDTA tube (BD). PBMCs were isolated using Ficoll-Paque PLUS (GE Healthcare, now 
Cytiva) as per manufacturer’s instructions. PBMCs were then stained using antibodies for flow cytometry 
analysis (Supplemental Table 3). The gating strategy is depicted in Supplemental Figure 1.
Following adipose tissue sample collection, samples were divided into a portion for flow cytometry (~0.1–
0.4 g) analysis; a portion for subsequent RNA extraction (~0.1–0.2 g), which was snap-frozen; and a sam-
ple fixed in 4% formaldehyde solution (MilliporeSigma) for future immunohistochemical analysis (~0.05–0.2 
g). The sample of adipose tissue aliquoted for flow cytometry analysis was first mechanically minced using 
microscopy scissors and then digested enzymatically using 5668 IU collagenase II (MilliporeSigma) and 55.5 
IU DNase (MilliporeSigma) per gram of adipose tissue for 30 minutes. Immune cells present in the stromal 
vascular fraction were obtained following centrifugation and lysed for red blood cells prior to antibody staining.
T cell stimulation assays. In a proportion of  patients where sufficient adipose tissue samples were avail-
able for further analyses, tissue was aliquoted for T cell stimulation assays. Briefly, PMA/ionomycin with 
the addition of  brefeldin A was used to stimulate the immune cell fraction of  the digested adipose tissue 
for 4 hours followed by IL-17, IL-22, and IFN-γ intracellular staining as shown in Supplemental Figure 1.
RT-PCR analysis. Total RNA was extracted from the adipose tissue using QIAzol (QIAGEN) and the 
RNeasy Lipid Tissue Mini Kits (QIAGEN) following the manufacturer’s instructions. Total RNA was extract-
ed from whole blood samples stored in PAXgene (PreAnalytiX) tubes using the PAXgene blood RNA kit 
(QIAGEN). RNA was quantified using the NanoDrop spectrophotometer (Thermo Fisher Scientific). Reverse 
transcription to cDNA was performed using High-Capacity RNA-to-cDNA kits (Applied Biosystems, Thermo 
Fisher Scientific) and stored at –80°C. The relevant primer sequences can be found in Supplemental Table 4 
and were purchased from Invitrogen, Thermo Fisher Scientific. Gene expression was performed using SYBR 
Green Supermix (Bio-Rad), as per manufacturer’s instructions, and analyzed using the Light Cycler System 
(Roche). Relative gene expression values were determined using the ΔΔCT method and normalized to a stable 
reference housekeeping gene control (GAPDH). The control values were set at 1. Given the ΔΔCT method 
is not normally distributed, the geometric mean was used for the representation of the data (40). Illumina 
sequencing was carried out at Novogene Bioinformatics Technology Ltd. Data were deposited in the National 
Center for Biotechnology Information’s Gene Expression Omnibus with accession number GSE179455.
Propensity matching of  groups. To account for differences in baseline clinical variables between 
groups, a propensity matching algorithm was applied. A 1:1 propensity score matching (PSM) optimal 
algorithm was utilized using dedicated propensity matching software (XLSTAT, Addisoft). The confi-
dence interval was set at 95% and a caliper width at 0.2. For the initial analysis comparing differences 
in severe versus nonsevere CAD, CABG and VR surgery were used as the dependent variables and age, 
sex, BMI, hypertension, hyperlipidemia, and diabetes as covariates. For the PSM of  subsequent group 
analyses, BMI and diabetes were used as dependent variables and age, sex, hypertension, and hyperlip-
idemia as covariates. For the hypertension group analysis, the variables to be matched for included age, 
sex, BMI, hyperlipidemia, and diabetes status.
Role of  comorbidities and cardiovascular risk factors in subgroup assessment. We evaluated cardiovascular risk 
factors that are known to impact adipose tissue specifically, namely obesity/overweight (4, 6), diabetes (15, 
27), and hypertension (5, 39), to determine the extent to which they alter the inflammatory profile in differ-
ent groups of  patients. All diabetic patients included had T2D.
Flow cytometry analysis, RT-PCR analysis, and T cell stimulation assays (as per the above methodolo-
gy) were undertaken to identify the key immune cells and mediators that differed between the groups. Com-
prehensive absolute changes in numbers of  all immune cells are available in Supplemental Figures 3–5.
Statistics. Power calculations were based an effect size of  1.16, power of  0.95, and α error of  0.05. Sta-
tistical significance was determined for continuous variables where 3 groups were assessed using the 2-way 
ANOVA (or Kruskal-Wallis for nonparametric data) test with Dunnett’s T3 (or Dunn’s for nonparametric 
data) multiple comparisons posttest applied. The 2-tailed Student’s t test was used for 2 groups of  continu-
ous data where the data were parametric and the Mann-Whitney U test for nonparametric data. The χ2 test 
or Fisher’s exact test was utilized for categorical data. Data were analyzed on GraphPad Prism version 8 
(GraphPad Software LLC). Normality was assessed using the Kolmogorov-Smirnov and Shapiro-Wilk tests. 
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Where parametric data are represented, the mean and standard deviation values are reported, and for non-
parametric data, median and interquartile ranges are reported. A P value of  less than 0.05 was considered 
statistically significant.
Study approval. The study was approved institutionally via the ethical framework of  the Barts BioRe-
source (research ethics committee reference: 14/EE/0007; London, United Kingdom), and written 
informed consent was obtained from each patient. Written consent was obtained prior to sample collection, 
and patients were identified with an arbitrary Barts BioResource number.
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